Last reviewed · How we verify
NCT07084038
Effect of Glycosuria on Urinary Protein in Patients With Chronic Kidney Disease Treated With SGLT2 Inhibitors
trial in Chronic Kidney Disease in 300 participants. Participants enrolled and being followed up; not accepting new ones.
30 June 2026
Quick facts
| Lead sponsor | Yuanjun Yang |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 July 2024 |
| Primary completion | 30 June 2026 |
| Estimated completion | 30 June 2026 |
| Sites | 1 location across China |
Conditions studied
- Chronic Kidney Disease — all drugs for Chronic Kidney Disease →
Sponsor
Yuanjun Yang
Who can join
18 and older, any sex, with Chronic Kidney Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial aims to investigate the correlation between glycosuria levels and urinary protein in chronic kidney disease patients treated with Sodium-Glucose Transporter 2 Inhibitors(SGLT2i), and to explore whether glycosuria can reflect the therapeutic response to SGLT2i in these patients. Through this study, the investigators hope to provide some clinical references for optimizing SGLT2i dosing strategies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07084038
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Kidney Disease
Currently open trials in the same condition.
- NCT07469540 — Effects of an Aerobic Exercise Program on Cardiovascular Risk in Patients With Chronic Kidney Disease or Rheumatoid Arth · NA · recruiting
- NCT07169422 — Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care · NA · recruiting
- NCT07481526 — A Prospecitve Multicenter, Observational Registry Study · recruiting
- NCT07450820 — OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD · recruiting
- NCT07107945 — A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease · Phase 3 · recruiting
Other Yuanjun Yang trials
Trials by the same sponsor.
- NCT06587997 — Changes in Renal Perfusion During Hemodialysis in Patients with End-stage Renal Disease · not yet recruiting
- NCT07003828 — Hemodialysis-Induced Renal Perfusion Decline: Unraveling the Pathophysiological Mechanisms Linking Intradialytic Circula · active not recruiting
- NCT06501222 — The Renal Protective Effects of Remote Ischemic Preconditioning in Patients With Chronic Kidney Disease · NA · recruiting
- NCT06275152 — The Protective Effect of Remote Ischemic Conditioning on Residual Renal Function in Hemodialysis Patients (RIC-HD) · NA · unknown
- NCT06243900 — NIRS for the Diagnosis of Residual Renal Function Injury in Hemodialysis Patients · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07084038 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yuanjun Yang
- Last refreshed: 3 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07084038.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing